{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-009859","form_type":"8-K","ticker":"GOVX","cik":"0000832489","company_name":"GeoVax Labs, Inc.","filed_at":"2025-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.471143+00:00","generated_at":"2026-05-24T03:30:05.841128+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"GeoVax FY2024 net loss $25.0M; BARDA award yields $4.0M revenue; key trials advancing","bullets":["Net loss $25.0M vs $26.0M in 2023; revenue of $4.0M from BARDA Project NextGen contract (no revenue in 2023).","Cash $5.5M at Dec 31, 2024, down from $6.5M; R&D expense $23.7M (up from $20.7M) on trial manufacturing.","BARDA $400M award supports 10,000-patient Phase 2b trial of GEO-CM04S1; manufacturing and sites confirmed.","DSMB cleared experimental arm of Phase 2 CLL trial after mRNA control arm failed primary endpoint.","Phase 2 booster data for GEO-CM04S1 in healthy adults expected H1 2025; GEO-MVA clinical eval expected H2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-009859","json":"https://secwatch.observer/filing/0001437749-25-009859.json","markdown":"https://secwatch.observer/filing/0001437749-25-009859.md","text":"https://secwatch.observer/filing/0001437749-25-009859.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/832489/000143774925009859/0001437749-25-009859-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/832489/000143774925009859/govx20250327_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T03:30:05.841128+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}